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Abstract 1 
Background and Aims:   Oxidized low-density lipoprotein (oxLDL) causes the development of 2 
atherosclerosis and kidney injury. Although circulating oxLDL levels were reportedly increased in type 2 3 
diabetic patients with macroalbuminuria, it remains unclear whether albuminuria or the reduced glomerular 4 
filtration rate (GFR) is independently associated with the circulating oxLDL level. This study aimed to 5 
elucidate the association between the stage of diabetic nephropathy and serum malondialdehyde-modified 6 
LDL (MDA-LDL) and the ratio of MDA-LDL to LDL-cholesterol (MDA-LDL/LDL). 7 
Methods and Results:  This retroactive cross-sectional study used data from 402 patients with type 2 8 
diabetes. Patients undergoing hemodialysis were excluded. Serum MDA-LDL levels were significantly 9 
increased with increases in severity of albuminuria (103 ± 44 U/L, 109 ± 54 U/L, and 135 ± 72 U/L for 10 
normoalbuminuria, microalbuminuria, and macroalbuminuria, respectively; P for trend = 0.020) but not 11 
according to the estimated GFR (eGFR). An increased MDA-LDL/LDL ratio was significantly associated 12 
with both increased albuminuria (35 ± 13, 37 ± 14, and 40 ± 15 for normoalbuminuria, microalbuminuria, and 13 
 3 
macroalbuminuria, respectively; P for trend = 0.003) and reduced eGFR (34 ± 13, 36 ± 13, 38 ± 12, and 51 ± 1 
28 for grade 1, 2, 3 and 4, respectively; P for trend = 0.002). Multiple linear regression analysis showed that 2 
neither the albumin excretion rate nor eGFR but ln-transformed triglycerides and LDL-C levels were 3 
independent determinants of both serum MDA-LDL levels and MDA-LDL/LDL ratios. 4 
Conclusion: Serum MDA-LDL levels and MDA-LDL/LDL ratios were increased in those with dyslipidemia 5 
associated with diabetic kidney disease.  6 
 7 
Keywords:  malondialdehyde-modified low-density lipoprotein; type 2 diabetes; albuminuria; estimated 8 
glomerular filtration rate; dyslipidemia 9 
 10 
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AER, albumin excretion rate: BMI, body mass index; CKD, chronic kidney disease; CVD, cardiovascular 12 
disease; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; EPA, eicosapentaenoic 13 
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acid; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density 1 
lipoprotein-cholesterol; ln AER, ln-transformed AER; ln HDL-C, ln-transformed HDL; ln TG, ln-transformed 2 
TG; MDA-LDL, malondialdehyde-modified low-density lipoprotein; MDA-LDL/LDL, MDA-LDL-to-LDL 3 
cholesterol ratio, oxLDL, oxidized low-density lipoprotein; TG, triglycerides 4 
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1. Background 1 
Diabetes mellitus is a high-risk state for atherosclerosis, leading to increased morbidity and mortality 2 
due to cardiovascular disease (CVD). It is also widely accepted that chronic kidney disease (CKD) presents a 3 
substantial risk for CVD. The presence of both diabetes and CKD is associated with a higher incidence of 4 
myocardial infarction and all-cause mortality compared with diabetes or CKD alone [1]. 5 
Oxidized low-density lipoprotein (oxLDL) has a pivotal role in the initiation and progression of 6 
atherosclerosis. oxLDL elicits foam cell formation, leading to increased release of inflammatory cytokines 7 
and chemokines from foam cells. It also stimulates medial smooth muscle cell migration into the intima, which 8 
was shown to be an important process for intimal thickening in atherosclerotic lesions [2]. Serum 9 
malondialdehyde-modified LDL (MDA-LDL), which is a type of oxidized LDL, was reported as a prognostic 10 
marker for future cardiac events in patients with stable angina and coronary stent implantation [3] or in diabetic 11 
patients with CAD [4].  The MDA-LDL-to-LDL cholesterol ratio (MDA-LDL/LDL) could predict the 12 
presence and development of coronary artery disease [5, 6]. The MDA-LDL/LDL was independently 13 
 6 
associated with the coronary artery calcification score in patients with hemodialysis [7].  1 
Recent studies have shown that oxLDL can contribute to the development of diabetic nephropathy 2 
through inducing injuries to podocytes [8], tubulointerstitial cells [9] and endothelial cells [10]. Production of 3 
collagen IV in mesangial cells was also reported as a contributor to the progression of diabetic nephropathy, 4 
which is stimulated by oxLDL-containing immune complexes [9]. Immunoglobulin G antibodies reacting with 5 
MDA-LDL lysine epitopes in circulating immune complexes were noted as a predictor of the development of 6 
macroalbuminuria in patients with type 2 diabetes [11]. Circulating oxLDL was reportedly increased in 7 
albuminuria in patients with diabetic nephropathy as well as in patients with end-stage renal diseases [12-14]. 8 
Although albuminuria was negatively correlated with the estimated glomerular filtration rate (eGFR) [15], 9 
there have been no studies on the association between oxLDL and eGFR in diabetes. Moreover, it is not clear 10 
whether albuminuria or eGFR is independently associated with circulating oxLDL levels.  11 
To elucidate the association between the stage of diabetic nephropathy and serum MDA-LDL or the 12 
MDA-LDL/LDL, we conducted a cross-sectional study of patients with type 2 diabetes.  13 
 7 
2. Methods 1 
2.1. Study participants  2 
We conducted a retrospective cross-sectional study using data on patients with type 2 diabetes who were 3 
admitted to the University of Tsukuba Hospital from January 2012 to December 2015. All patients had 4 
undergone a structured interview, physical examination, and laboratory analysis. We excluded data on patients 5 
undergoing hemodialysis, with the complications of diabetic ketoacidosis, hyperglycemia hyperosmolar 6 
syndrome, viral hepatitis, liver cirrhosis, malignancy, endocrine disorders affecting serum lipid levels, 7 
infectious diseases, inflammatory diseases, pregnancy, renal diseases other than diabetic kidney disease, and 8 
the use of systemic glucocorticoids, and who were under 20 years of age. Hypertension was defined as systolic 9 
blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg and/or the current use of 10 
antihypertensive agents. This retrospective study was approved by the Ethics Committee of the University of 11 
Tsukuba Hospital and conducted according to the Declaration of Helsinki.  12 
2.2. Laboratory Analysis 13 
 8 
Blood samples were collected in the morning after an overnight fast within 3 days after admission. 1 
Plasma glucose and serum total cholesterol, high-density lipoprotein-cholesterol (HDL-C), triglycerides (TG), 2 
and creatinine levels were determined using an automated analyzer (7700 clinical analyzer; Hitachi High-3 
Technologies Corporation, Tokyo, Japan). HbA1c was measured by high-performance liquid chromatography 4 
(Tosoh Corporation, Tokyo, Japan). Serum LDL-C levels were measured by a homogeneous assay (Sekisui 5 
Medical, Tokyo, Japan). Serum concentrations of MDA-LDL were quantitated by an enzyme-linked 6 
immunosorbent assay (Sekisui Medical, Tokyo, Japan). Albumin excretion rate (AER) was measured using 7 
24-hour urine specimens. eGFR was calculated using an equation modiﬁed for the Japanese: eGFR = 194 × 8 
sCre- 1.0949 × Age-0.287 × 0.739 (if female) [16]. AER and eGFR were categorized according to the 2012 Kidney 9 
Disease: Improving Global Outcomes clinical practice guidelines [17]. 10 
2.3. Statistical Analysis 11 
Continuous variables were expressed as mean ± SD or median and interquartile range based on distribution. 12 
Values of TG, HDL-C, and AER were log transformed due to their non-normal distribution. MDA-LDL-13 
 9 
related variables (MDA-LDL and MDA-LDL/LDL) and lipid parameters were stratified by nephropathy 1 
categories (AER <30, ≥30<300, or ≥300 mg/day; eGFR ≥90, ≥60<90, ≥30<60, or <30 ml/min/1.73m2) and 2 
were compared by the Kruskal–Wallis test because homogeneities of variance were not assumed for all 3 
variables. A Jonckheere–Terpastra test was used to analyze trends through categories. A Pearson’s correlation 4 
coefficient or a Spearman’s correlation coefficient was used to examine bivariate associations between MDA-5 
LDL-related variables and clinical parameters, depending on distributions of the values of the parameters. A 6 
multiple linear regression analysis was performed to study independent determinants of MDA-LDL-related 7 
variables. A logistic regression analysis was conducted to examine whether MDA-LDL-related variables were 8 
independent predictors of the presence of CVD. Statistical analyses were performed using the Statistical 9 
Package for Social Science Statistics (version 23.0; Chicago, IL, USA). Statistical significance was considered 10 
at a P value of <0.05. 11 
  12 
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3. Results 1 
3.1. Characteristics of Participants 2 
Initially, data on 1,014 patients with type 1 and type 2 diabetes were examined; however, patients 3 
were excluded for the following reasons: undergoing hemodialysis (n = 6), diabetic ketoacidosis or 4 
hyperglycemia hyperosmolar syndrome (n = 40), acute illness (n = 88), perioperative period (n = 3), viral 5 
hepatitis and/or liver cirrhosis (n = 40), malignancy (n = 135), endocrine disorders affecting serum lipid levels 6 
(n = 121), inflammatory diseases (n = 24), pregnancy (n = 33), renal diseases other than diabetic kidney disease 7 
(n = 14), use of systemic glucocorticoids (n = 33), MDA-LDL and/or other lipid parameters not measured (n 8 
= 15), and age under 20 years (n = 6). After these exclusions, 456 patients were eligible for analysis. Of these, 9 
we analyzed data on 402 patients who had type 2 diabetes.  10 
Table 1 shows the characteristics of the study participants. Their mean age was 57 ± 13 years, median 11 
duration of diabetes was 9.0 (3.0 - 16.0) years, mean body mass index (BMI) was 27.0 ± 5.4 kg/m2, mean 12 
fasting plasma glucose (FPG) was 9.4 ± 2.7 mmol/L, and mean HbA1c level was 9.9 ± 1.9%. In terms of 13 
 11 
renal function, the mean eGFR was 86.6 ± 29.5 mL/min/1.73m2 and median AER was 13.8 (6.2 - 47.7) 1 
mg/day. The mean MDA-LDL value and MDA-LDL/LDL were 107 ±  50 U/L and 36 ±  14 2 
[U/L]/[mmol/L], respectively. 3 
Almost half of the patients were treated with sulfonylureas, metformin, and/or dipeptidyl peptidase-4 (DPP-4 
4) inhibitors (41%, 41%, and 47%, respectively). Thirty-eight percent of patients were prescribed renin-5 
angiotensin system inhibitors. Statins were used by 38% of patients and other lipid lowering drugs were 6 
prescribed for smaller groups (fibrate, ezetimib, and eicosapentaenoic acid [EPA] for 3%, 2%, and 3% of 7 
participants, respectively). 8 
3.2. Associations between MDA-LDL-related variables and renal function 9 
Table 2 shows the associations between the AER and lipid parameters. Serum MDA-LDL levels trended 10 
towards a positive association according to worsening of the category of albuminuria (p = 0.006, p for trend 11 
= 0.020), and the MDA-LDL/LDL showed a significant positive association as the category of albuminuria 12 
worsened (p = 0.008, p for trend = 0.003). As shown in Table 3, MDA-LDL levels did not differ significantly 13 
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among the categories of eGFR (p = 0.321, p for trend = 0.527). On the other hand, the MDA-LDL/LDL had 1 
a significant positive association with deterioration of the eGFR (p = 0.013, p for trend = 0.002). 2 
3.3. Associations between MDA-LDL-related variables and clinical parameters 3 
As shown in Table 4, MDA-LDL levels were positively correlated with diastolic blood pressure, FPG, HbA1c, 4 
ln-transformed AER (ln AER), ln-transformed TG (ln TG), and LDL (p = <0.001, 0.006, <0.001, <0.001, 5 
<0.001, and <0.001, respectively), whereas they were inversely correlated with age, taking statins, and ln-6 
transformed HDL (ln HDL-C) (p = <0.001, <0.001, and 0.001, respectively). The levels of MDA-LDL/LDL 7 
had a positive correlation with hypertension, CVD, ln AER, statins, and ln TG (p = 0.003, <0.001, 0.002, 8 
<0.001, and <0.001, respectively), whereas there was an inverse correlation with eGFR, ln HDL-C, and LDL-9 
C (p = 0.005, <0.001, and <0.001, respectively).  10 
3.4. Multiple linear regression analyses of MDA-LDL-related variables 11 
To determine the clinical parameters that were independently associated with MDA-LDL-related variables, a 12 
multiple linear regression analysis was performed that included the following variables: age, sex, CVD, 13 
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current smoking, BMI, hypertension, FPG, HbA1c, eGFR, ln AER, ln TG, ln HDL-C, LDL-C, taking statins 1 
and/or ezetimib, taking fibrates and/or EPA, and taking renin-angiotensin system inhibitors. Results showed 2 
that not AER nor eGFR but LDL-C and ln TG were independent determinants of both MDA-LDL and MDA-3 
LDL/LDL (adjusted R2 = 0.451 and 0.332, respectively) (Table 5). 4 
3.5. Logistic regression analyses of MDA-LDL-related variables 5 
Logistic regression analyses showed that MDA-LDL/LDL was an independent predictor of CVD but that 6 
MDA-LDL was not after adjustments for age, sex, duration of diabetes, hypertension, smoking, dyslipidemia, 7 
eGFR and AER (model 1) or age, sex, duration of diabetes, hypertension, smoking, dyslipidemia and diabetic 8 
kidney disease (model 2) (Supplemental Table 1).9 
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4. Discussion 1 
In this study, we examined the association between the stage of diabetic nephropathy and serum 2 
MDA-LDL-related variables. There were three major findings in the current study. First, serum MDA-LDL 3 
levels were significantly increased with increases in the severity of albuminuria but not with those of eGFR. 4 
Second, both increased albuminuria and reduced eGFR were significantly associated with an increased MDA-5 
LDL/LDL. Third, multiple linear regression analyses showed that not albuminuria nor eGFR but ln TG and 6 
LDL-C levels were independent determinants of both serum MDA-LDL levels and the MDA-LDL/LDL.  7 
Whether circulating oxLDL levels are increased in patients with type 2 diabetes with severe 8 
albuminuria is controversial. It was shown that serum oxLDL levels were increased in type 2 diabetic patients 9 
with macroalbuminuria [13, 18] which is consistent with this study, but one study could not find such an 10 
association [19]. Since AER levels are negatively correlated with eGFR and Honda et al. reported that serum 11 
MDA-LDL levels were significantly lower in patients with CKD stage 5 than in those with CKD stage 2-3 or 12 
stage 4 [20], it is possible that a decreased eGFR obscures the association between serum oxLDL levels and 13 
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severity of albuminuria. However, this possibility is unlikely because serum MDA-LDL levels had a 1 
significant positive association with the AER but no significant association was observed between serum 2 
MDA-LDL levels and the eGFR in the current study.  3 
In the current study, the MDA-LDL/LDL was significantly correlated with both albuminuria and 4 
eGFR in bivariate analyses. However, those associations did not persist after adjustment for confounding 5 
factors. To our knowledge, this is the first investigation of the association between MDA-LDL/LDL and 6 
albuminuria or eGFR. It was shown that the oxLDL-to-LDL-C ratio or MDA-LDL/LDL was a superior 7 
predictor of coronary artery disease compared with the serum MDA-LDL level in cross-sectional studies [5, 8 
21] and a prospective study [22]. Both increased urinary albumin levels and decreased eGFRs were reportedly 9 
independent predictors of CVD in type 2 diabetes [23-25]. In the current study, not serum MDA-LDL levels 10 
but the MDA-LDL/LDL was an independent predictor of CVD after adjustment for confounding factors 11 
including AER and eGFR or complicating diabetic kidney disease.  12 
It was shown that serum oxLDL or MDA-LDL levels had positive associations with serum TG and 13 
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LDL-C levels [26-28] and negative associations with serum HDL-C levels [28]. Dyslipidemia in CKD is 1 
characterized by elevated serum TG levels and increased proportions of small dense LDL particles and 2 
decreased serum HDL-C [29]. Serum LDL-C values are increased according to the severity of albuminuria 3 
[30]. The current results showed that serum ln TG and LDL-C were significantly and positively correlated 4 
with serum MDA-LDL levels in bivariate analyses. MDA-LDL/LDL had a significantly positive correlation 5 
with ln TG and a negative correlation with LDL-C. Serum HDL-C levels had a significantly negative 6 
correlation with both serum MDA-LDL and the MDA-LDL/LDL. Serum ln TG and LDL-C but not serum ln 7 
HDL-C, ln AER, and eGFR were independent determinants of serum MDA-LDL levels and MDA-LDL/LDL 8 
in multiple linear regression analyses. The studies in which serum TG and/or LDL-C were increased according 9 
to the severity of albuminuria showed significantly increased serum oxLDL levels in macroalbuminuria in 10 
type 2 diabetes [13, 18]. On the other hand, serum LDL-C values seemed not to be different among categories 11 
of albuminuria in the study that showed no association between serum oxLDL levels and severity of 12 
albuminuria [19]. Consequently, increased serum MDA-LDL and MDA-LDL/LDL accompanied by increased 13 
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AERs or decreased eGFRs probably result from dyslipidemia associated with diabetic kidney disease.  1 
There is limited evidence of the association between MDA-LDL or oxLDL and CKD in nondiabetic 2 
study participants. Kuchta and colleagues reported that plasma oxLDL levels were significantly increased in 3 
all stages (stage 3, stage 4, stage 5, hemodialysis and peritoneal dialysis) of CKD including that in patients 4 
with diabetes in addition to CKD in comparison with healthy study participants [31]. They also showed that 5 
mean plasma TG levels in all CKD groups were higher than that in healthy individuals [31]. However, this 6 
study did not analyze the association between circulating oxLDL levels and TG levels with bivariate or 7 
multivariate analysis so it remains unclear whether the association between circulating oxLDL levels and CKD 8 
stages is independent of dyslipidemia. 9 
Although serum levels of TG and LDL-C were the only independent determinants of both serum 10 
MDA-LDL levels and MDA-LDL/LDL, these lipid parameters could only contribute less than 50% to the 11 
value of MDA-LDL-related variables (Table 5). The logistic regression analyses showed that the MDA-12 
LDL/LDL was an independent determinant of the presence of CVD after adjustments for age, sex, duration of 13 
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diabetes, hypertension, smoking, dyslipidemia and diabetic kidney disease. Therefore, measuring serum 1 
MDA-LDL levels in addition to serum lipid levels could provide further information when assessing 2 
cardiovascular risk in patients with advanced diabetic kidney disease. 3 
Several limitations of this study should be addressed. First, it was retrospective and cross-sectional, 4 
which does not allow us to derive any cause–effect relationship. Although both AER and eGFR were not 5 
independent determinants of MDA-LDL-related variables in this study, the possibility that increased MDA-6 
LDL or MDA-LDL/LDL promotes albuminuria and/or an eGFR decline is not excluded. Moreover, there was 7 
a small number of participants with macroalbuminuria or an eGFR of less than 30 mL/min/1.73 m2. Therefore, 8 
we might have underestimated the association between MDA-LDL or MDA-LDL/LDL and albuminuria or 9 
eGFR in the multivariate analyses. Serum LDL-C and ln TG were independent determinants of MDA-LDL-10 
related variables. Seventy percent of the participants with CVD were taking lipid-lowering drugs in contrast 11 
to 34% of those without CVD. Thus, taking lipid-lowering drugs could obscure the association between the 12 
MDA-LDL-related variables and the risk of CVD (data not shown). Second, most of our patients had been 13 
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hospitalized for poor glycemic control. These issues could have introduced selection bias. Our results should 1 
be confirmed in prospective studies. 2 
In conclusion, increased serum MDA-LDL levels and MDA-LDL/LDL in type 2 diabetic patients with 3 
albuminuria or decreased eGFR possibly results from dyslipidemia associated with diabetic kidney disease.  4 
 5 
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Table 1. Clinical characteristics of participants 
n      402   
Female, n (%) 159 (40) Antidiabetic drugs, n (%)  
Age (year) 57 ± 13  Sulfonylureas 164 (41) 
Duration of diabetes (year) 9.0 (3.0 − 16.0)  Metformin 164 (41) 
Body mass index (kg/m2) 27.0 ± 5.4  Thiazolidinedione 27 (7) 
Hypertension*, n (%) 278 (69)  Glinides 11 (3) 
Systolic blood pressure (mmHg) 134 ± 20  α-Glucosidase inhibitors 59 (15) 
Diastolic blood pressure (mmHg) 78 ± 13  DPP-4 inhibitors 190 (47) 
Current smoker, n (%) 107 (27)  GLP-1 receptor agonists 15 (4) 
Cardiovascular disease, n (%) 84 (21)  SGLT-2 inhibitors 4 (1) 
Estimated GFR (mL/min/1.73m2) 86.6 ± 29.5  Insulin 133 (33) 
Albumin excretion rate (mg/day) 13.8 (6.2 - 47.7) Antihypertensive drugs, n (%)  
Fasting plasma glucose (mmol/L) 9.4 ± 2.7  Renin-angiotensin system inhibitors 
154 
(38) 
HbA1c (%) 9.9 ± 1.9  Calcium channel blockers 138 (34) 
C-reactive protein (mg/dL) 0.80 (0.03 − 0.23)  Diuretics 49 (12) 
Total cholesterol (mmol/L) 5.0 ± 1.2  β-blockers 35 (8) 
Triglycerides (mmol/L) 1.6 (1.1 − 2.2) Lipid lowering drugs  
HDL cholesterol (mmol/L) 1.09 (0.92 − 1.30)  Statins 
152 
(38) 
LDL cholesterol (mmol/L) 3.1 ± 1.0  Fibrates 11 (3) 
MDA-LDL (U/L) 107 ± 50  Ezetimibe 7 (2) 
MDA-LDL/LDL ([U/L] / [mmol/L]) 36 ± 14  Eicosapentaenoic acid 12 (3) 
Data are mean ± SD or median (interquartile range). Hypertension: systolic blood pressure ≥ 
140 and/or diastolic blood pressure ≥ 90 or taking antihypertensive drugs. DPP-4, dipeptidyl 
peptidase-4; GFR, glomerular filtration rate; GLP-1, glucagon-like peptide-1; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; MDA-LDL, malondialdehyde-modified 
low-density lipoprotein; MDA-LDL/LDL, MDA-LDL-to-LDL cholesterol ratio; SGLT-2, 
sodium-glucose cotranspoter-2
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Table 2. Associations between albumin excretion rate and lipid parameters 
 Albumin excretion rate（mg/day） P P for trend 
 < 30 30 - < 300 300 -   
n 266 97 39   
MDA-LDL (U/L) 103 ± 44 109 ± 54 135 ± 72*††  0.006  0.020 
MDA-LDL/LDL ([U/L] / [mmol/L]) 35 ± 13 37 ± 14 40 ± 15*  0.008  0.003 
Total cholesterol (mmol/L) 4.9 ± 1.0 4.9 ± 1.2 5.9 ± 2.0*†  0.012  0.298 
Triglycerides (mmol/L) 1.5 (1.1 − 2.1) 1.7 (1.1 − 2.6) 2.3 (1.7 − 3.5)***†† < 0.001 < 0.001 
HDL cholesterol (mmol/L) 1.10 (0.93 − 1.37) 1.07 (0.91 − 1.24) 1.09 (0.89 − 1.24)  0.124  0.044 
LDL cholesterol (mmol/L) 3.0 ± 0.9 3.0 ± 1.0      3.4 ± 1.5  0.306  0.952 
Data are mean ± SD or median (interquartile range). *P <0.05 and ***P <0.001 vs. albumin excretion rate of <30. †P <0.05 and ††P 
<0.01 vs. albumin excretion rate of 30 - <300. HDL; high-density lipoprotein; LDL, low-density lipoprotein; MDA-LDL, 
malondialdehyde-modified low-density lipoprotein; MDA-LDL/LDL, MDA-LDL-to-LDL cholesterol ratio. 
 
 
 
 27 
 
Table 3. Associations between estimated GFR and serum lipid parameters 
 Estimated GFR (mL/min/1.73m2) P P for trend 
 90 - < 90 - 60 < 60 - 30 < 30   
n 172 158 61 11   
MDA-LDL (U/L) 108 ± 50 107 ± 49 100 ± 45 141 ± 90 0.321 0.527 
MDA-LDL/LDL ([U/L] / [mmol/L]) 34 ± 13 36 ± 13 38 ± 12 51 ± 28 0.013 0.002 
Total cholesterol (mmol/L) 5.2 ± 1.1 5.0 ± 1.3 4.6 ± 1.2* 5.2 ± 1.5 0.002 < 0.001 
Triglycerides (mmol/L) 1.6 (1.1 − 2.2) 1.5 (1.1 − 2.1) 1.7 (1.3 − 2.4) 2.3 (2.0 − 2.6)†  0.019 0.424 
HDL cholesterol (mmol/L) 1.10 (0.96 − 1.35) 1.13 (0.97 − 1.33) 0.98 (0.85 − 1.13)**†† 0.89 (0.74 − 1.08) < 0.001 0.001 
LDL cholesterol (mmol/L) 3.2 ± 0.9 3.1 ± 1.0      2.7 ± 1.0***† 2.9 ± 1.1 < 0.001 < 0.001 
Data are mean ± SD or median (interquartile range). *P <0.05, **P <0.01 and **P <0.001 vs. eGFR of 90 -, †P <0.05 and ††P <0.01 vs. 
eGFR of <90 – 60. HDL; high-density lipoprotein; LDL, low-density lipoprotein; MDA-LDL, malondialdehyde-modified low-density 
lipoprotein; MDA-LDL/LDL, MDA-LDL-to-LDL cholesterol ratio 
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Table 4. Correlations between MDA-LDL-related variables and clinical parameters 
  MDA-LDL MDA-LDL/LDL 
  r P r P 
Age -0.221 <0.001 -0.049 0.326 
Systolic blood pressure 0.047 0.350 0.017 0.734 
Diastolic blood pressure  0.187 < 0.001 0.088 0.077 
Hypertension a) -0.007 0.885 0.150 0.003 
Cardiovascular disease a) -0.095 0.056 0.178 < 0.001 
Fasting plasma glucose 0.137 0.006 0.074 0.136 
HbA1c 0.180 <0.001 0.032 0.528 
Estimated GFR -0.001 0.989 -0.138 0.005 
ln Albumin excretion rate 0.200 < 0.001 0.157 0.002 
Statins a) -0.188 < 0.001 0.199 < 0.001 
Fibrates a) -0.028 0.578 -0.028 0.579 
ln Triglycerides 0.486 < 0.001 0.504 < 0.001 
ln HDL cholesterol -0.158 0.001 -0.259 < 0.001 
LDL cholesterol 0.547 < 0.001 -0.182 < 0.001 
Parametric values are tested by Pearson’s correlation. a) Non-parametric values are tested 
by Spearman’s correlation. GFR, glomerular filtration rate; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; ln HDL cholesterol, ln-transformed high-
density lipoprotein cholesterol; ln triglycerides, ln-transformed triglycerides; MDA-LDL, 
malondialdehyde-modified low-density lipoprotein; MDA-LDL/LDL, MDA-LDL-to-
LDL cholesterol ratio
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Table 5. Multivariate association of MDA-LDL-related variables with clinical parameters 
BMI, body mass index; eGFR, estimated glomerular filtration rate; ln AER, ln-transformed albumin excretion rate; ln Triglycerides, ln-transformed 
triglycerides; ln HDL, ln-transformed high-density lipoprotein; LDL, low-density lipoprotein; EPA, eicosapentaenoic acid; MDA-LDL, 
malondialdehyde-modified-low density lipoprotein; MDA-LDL/LDL, MDA-LDL-to-LDL cholesterol ratio 
 
 MDA-LDL (Adjusted R2 = 0.451) MDA-LDL/LDL (Adjusted R2 = 0.332) 
Covariates  β Standard Error P β Standard Error P 
Age 
Sex 
Cardiovascular disease 
Current smoker 
BMI 
Hypertension 
Fasting plasma glucose 
HbA1c 
eGFR 
ln AER 
ln Triglycerides 
ln HDL cholesterol 
LDL cholesterol 
Taking statins and/or ezetimibe 
Taking fibrates and/or EPA 
Taking renin-angiotensin system inhibitors 
-0.107 
3.243 
1.531 
-6.638 
-0.596 
4.400 
-1.261 
2.063 
-0.082 
0.291 
38.185 
1.792 
24.518 
-2.823 
-4.887 
1.463 
0.192 
4.224 
5.136 
4.734 
0.408 
5.245 
0.845 
1.187 
0.082 
1.228 
3.556 
9.343 
1.928 
4.642 
8.311 
4.879 
0.579 
0.443 
0.766 
0.162 
0.145 
0.402 
0.136 
0.083 
0.317 
0.813 
< 0.001 
0.848 
< 0.001 
0.543 
0.557 
0.764 
-0.054 
0.817 
0.933 
-2.356 
-0.236 
1.204 
-0.420 
0.566 
-0.027 
-0.019 
15.286 
1.021 
-4.084 
-1.258 
-1.766 
1.870 
0.058 
1.269 
1.543 
1.422 
0.123 
1.576 
0.254 
0.357 
0.025 
0.369 
1.390 
2.807 
0.692 
1.395 
2.497 
1.466 
0.346 
0.520 
0.546 
0.098 
0.055 
0.445 
0.099 
0.113 
0.266 
0.958 
< 0.001 
0.716 
<0.001 
0.368 
0.480 
0.203 
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Supplemental Table. Logistic regression models for variables associated with the presence of cardiovascular disease 
 
 
 
 
 
 
 
 
 
Hypertension, systolic blood pressure ≥ 140 and/or diastolic blood pressure ≥ 90 and/or taking antihypertensive drugs; Smoking, having current 
and/or ever smoking history; Dyslipidemia, serum triglycerides levels ≥ 1.7 mmol/L and/or serum high-density lipoporotein cholesterol levels < 
1.03 mmol/L and/or low-density lipoprotein cholesterol levels ≥ 3.62 mmol/L and/or taking lipid-lowering drugs; eGFR, estimated glomerular 
filtration rate; AER, albumin excretion rate; Diabetic kidney disease, eGFR < 60 and/or AER ≥ 30 mg/day; MDA-LDL, malondialdehyde-
modified-low density lipoprotein; MDA-LDL/LDL, MDA-LDL-to-LDL cholesterol ratio; OR, odds ratio; CI, confidence interval 
 
 Model 1     Model 2    
 OR (95% CI) P OR (95% CI) P   OR (95% CI) P OR (95% CI) P  
Age 1.03 (1.01 − 1.06) 0.010 1.04 (1.01 − 1.07) 0.003  1.04 (1.02 − 1.07) 0.001 1.04 (1.02 − 1.07) 0.000 
Male sex 0.92 (0.46 − 1.82) 0.808 0.85 (0.43 − 1.70) 0.651  0.90 (0.46 − 1.78) 0.769 0.83 (0.42 − 1.63) 0.580 
Duration of diabetes 1.03 (1.00 − 1.06) 0.039 1.03 (1.00 − 1.06) 0.024  1.03 (1.00 − 1.06) 0.032 1.03 (1.00 − 1.07) 0.022 
Hypertension 4.13 (1.81 − 9.43) 0.001 3.92 (1.71 − 8.97) 0.001  3.79 (1.65 − 8.70) 0.002 3.57 (1.55 − 8.19) 0.003 
Smoking 1.99 (0.98 − 4.07) 0.058 2.09 (1.03 − 4.25) 0.042  1.93 (0.96 − 3.89) 0.065 2.04 (1.01 − 4.13) 0.046 
Dyslipidemia 1.52 (0.69 − 3.32) 0.292 1.33 (0.60 − 2.92) 0.484  1.65 (0.76 − 3.60) 0.208 1.38 (0.63 − 3.05) 0.419 
eGFR 0.99 (0.98 − 1.00) 0.085 0.99 (0.98 − 1.00) 0.178  − − − − 
AER 1.00 (1.00 − 1.00) 0.596 1.00 (0.90 − 1.00) 0.439  −     − − − 
Diabetic kidney disease − − − −  1.82 (1.06 − 3.15) 0.031 1.64 (0.95 − 2.85) 0.077 
MDA-LDL 1.00 (0.99 − 1.00) 0.466 − −  1.00 (0.99 − 1.00) 0.349 − − 
MDA-LDL/LDL − − 1.02 (1.00 − 1.04) 0.032  − − 1.02 (1.00 − 1.04) 0.035 
